Table 1.
Demographic and clinical characteristics of CLD patients.
| Total patients with CLD (n = 237) | Above 180 days after the second dose (n = 24) | Below 120 days after booster dose (n = 22) | 121–180 days after booster dose (n = 38) | Above 180 days after booster dose (n = 153) | P value | |
|---|---|---|---|---|---|---|
| Age (year) | 47.01 (12.00) | 48.00 (12.51) | 41.32 (10.81) | 46.84 (14.64) | 47.84 (11.23) | 0.119 |
| Male/female, n | 154/83 | 16/8 | 12/10 | 27/11 | 99/54 | 0.636 |
| Type of CLD, n (%) | ||||||
| Hepatitis Ba | 144 (60.76) | 11 (45.83) | 12 (54.55) | 23 (60.53) | 98 (64.05) | 0.348 |
| Hepatitis Ca | 10 (4.22) | 1 (4.17) | 1 (4.55) | 1 (2.63) | 7 (4.58) | 0.962 |
| Cirrhosis | 53 (22.36) | 5 (20.83) | 5 (22.73) | 10 (26.32) | 33 (21.57) | 0.934 |
| Otherb | 30 (12.66) | 7 (29.17) | 4 (18.18) | 4 (10.53) | 15 (9.80) | 0.050 |
| Treatments, n (%) | 187 (78.90) | 18 (75.00) | 16 (72.73) | 29 (76.32) | 124 (81.05) | 0.730 |
| Antiviral treatmentc, n (%) | 163 (68.78) | 16 (66.67) | 14 (63.64) | 27 (71.05) | 106 (69.28) | 0.934 |
| Chinese patent medicinesd, n (%) | 53 (22.36) | 6 (25.00) | 10 (45.45) | 10 (26.32) | 27 (17.65) | 0.027 |
| Hepatitis B parameters | ||||||
| HBsAg (IU/mL) | 1370 (266.8, 3960) | 291.2 (11.51, 4166) | 957.7 (96.92, 4647) | 792.7 (95.83, 4595) | 1822 (357,3926) | 0.715 |
| HBsAg (+), n (%) | 119 (50.21) | 8 (33.33) | 14 (63.64) | 20 (52.63) | 77 (50.33) | 0.220 |
| HBsAg (mIU/mL) | 0.89 (0.5, 3.05) | 0.5 (0.06, 1.60) | 0.53 (0.5, 2.08) | 1.79 (0.5, 5.49) | 1 (0.5, 3.12) | 0.128 |
| HBsAb (+), n (%) | 9 (3.80) | 0 (0.00) | 2 (9.09) | 1 (2.63) | 6 (3.92) | 0.426 |
| HBeAg (+), n (%) | 45 (18.99) | 3 (12.50) | 6 (27.27) | 9 (23.68) | 27 (17.65) | 0.501 |
| HBeAb (+), n (%) | 64 (27.00) | 7 (29.17) | 8 (36.36) | 11 (28.95) | 38 (24.84) | 0.689 |
| HBcAb (+), n (%) | 107 (45.15) | 9 (37.50) | 14 (63.64) | 16 (42.11) | 68 (44.44) | 0.287 |
| HBV DNA (+), n (%) | 46 (19.41) | 2 (8.33) | 7 (31.82) | 7 (18.42) | 30 (19.61) | 0.253 |
| Liver function parameters | ||||||
| Alanine aminotransferase (U/L) | 23.60 (17.20, 36.35) | 22.50 (16.10, 31.45) | 27.90 (18.80, 55.43) | 23.95 (18.03, 37.18) | 23.90 (17.28, 35.70) | 0.516 |
| Aspartate aminotransferase (U/L) | 22.70 (17.70, 29.15) | 23.70 (15.80, 31.70) | 23.45 (18.50, 32.85) | 21.15 (16.95, 25.28) | 22.40 (17.58, 29.25) | 0.601 |
| γ-glutamyl transferas (U/L) | 20.80 (15.25, 33.25) | 25.90 (16.55, 53.85) | 24.75 (16.18, 46.10) | 17.70 (11.60, 27.58) | 20.80 (15.38, 32.23) | 0.090 |
| Alkaline phosphatase (U/L) | 82 (69, 102) | 81 (64, 110.5) | 87 (72.75, 108) | 76 (66.25, 90.75) | 83 (69, 104) | 0.264 |
| Total bilirubin (μmol/L) | 14.20 (11.30, 19.95) | 12.80 (11.25, 22.55) | 14.30 (11.68, 20.75) | 14.75 (12.43, 19.88) | 14.10 (10.58, 19.85) | 0.575 |
| Direct bilirubin (μmol/L) | 4.40 (3.10, 6.05) | 4.10 (3.50, 7.95) | 4.60 (3.35, 6.65) | 4.55 (3.90, 7.05) | 4.35 (3.00, 6.00) | 0.437 |
| Total biliary acid (μmol/L) | 3.40 (2.30, 9.30) | 2.90 (1.80, 7.00) | 3.10 (2.30, 16.00) | 3.40 (2.35, 53.45) | 3.50 (1.70, 8.70) | 0.724 |
| Total protein (g/L) | 75.70 (72.60, 77.80) | 72.20 (67.90, 78.10) | 76.15 (74.18, 79.03) | 74.10 (71.45, 77.73) | 76.05 (73.05, 77.80) | 0.112 |
| Albumin (g/L) | 46.20 (43.90, 48.1) | 44.40 (38.00, 47.10) | 46.65 (44.58, 47.65) | 46.00 (43.50, 48.10) | 46.40 (44.25, 48.33) | 0.256 |
| Prealbumin (mg/L) | 200.30 (84.37) | 216.30 (58.67) | 235.80 (96.76) | 240.70 (144.80) | 187.60 (72.46) | 0.361 |
| Lactate dehydrogenase (U/L) | 177.5 (157.3, 200) | 190 (158.3, 210.3) | 172 (157, 209) | 177 (160, 212) | 178 (156.3, 196) | 0.785 |
| Cholinesterase (U/L) | 8301 (4784, 10207) | 7526 (5291, 10213) | 9432 (5234, 11183) | 7453 (4235, 10585) | 8511 (4617, 9908) | 0.715 |
| Blood cell counts | ||||||
| White blood cells ( × 109/L) | 5.12 (4.19, 6.44) | 6.19 (4.31, 7.48) | 5.13 (3.97, 6.26) | 4.92 (3.97, 6.14) | 5.07 (4.21, 6.5) | 0.485 |
| Lymphocytes ( × 109/L) | 1.75 (1.25, 2.10) | 1.76 (1.54, 2.67) | 1.89 (1.43, 2.16) | 1.68 (1.23, 1.96) | 1.70 (2.07, 2.07) | 0.621 |
Normally distributed data are shown as mean (standard deviation), non-normally distributed data are shown as median (Q1, Q3).
HBsAg, hepatitis B surface antigen; HBsAb, hepatitis B surface antibody; HBeAg, hepatitis B envelope antigen; HBeAb, hepatitis B envelope antibody; HBcAb, hepatitis B core antibody.
Viral hepatitis has not yet progress to cirrhosis.
Other CLD included primary biliary cholangitis, alcoholic hepatitis, fatty liver, toxic hepatitis, liver cancer.
Antiviral drugs include entecavir, tenofovir disoproxil fumarate, tenofovir disoproxil fumarate, sofosbuvir velpatasvir, elbavir glarevir, tenofovir ami, pegylated interferon.
Chinese patent medicines include silymarin, Ruangan Huajian Granules, Fuzheng Huayu Preparation, Dahuang Zhechong Pills, Chaihuangyigan Granule, compound Yiganling, Biejiajianwan.